The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Could BTKis play a role in DLBCL through rational combinations?
In this video, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, briefly discusses whether BTK inhibitors (BTKis) may still play a role in diffuse large B-cell lymphoma (DLBCL) through rational combinations, highlighting the promising data with acalabrutinib, lenalidomide, and rituximab in the upfront setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
